A decade ago, healthcare software was largely viewed as a supporting tool for hospitals and physicians. Today, digital therapeutics (DTx) has evolved into a rapidly growing healthcare segment capable of delivering clinically validated interventions for chronic diseases, mental health disorders, and complex conditions such as chronic kidney disease (CKD).
The industry’s transformation is being fueled by a simple reality: healthcare systems worldwide are struggling to manage growing patient populations, rising treatment costs, and shortages of healthcare professionals.
According to the World Health Organization (WHO), nearly 1 billion people worldwide live with a mental disorder, while chronic kidney disease affects approximately 850 million people globally. As these patient populations continue to grow, digital therapeutics companies are racing to provide scalable, software-driven treatment solutions.
The result is an increasingly competitive market where specialized digital therapeutics companies are competing not only against each other, but also against hospitals, pharmaceutical manufacturers, telehealth providers, and traditional care models.
The Market Opportunity Driving Competition
The global digital therapeutics market has entered a phase of rapid expansion.
According to Towards Healthcare Research and Consulting Industry reports estimate that the market was valued at approximately USD 9.84 billion in 2025 and is projected to exceed USD 114.37 billion by 2035, representing a CAGR of nearly 28%.
North America currently accounts for more than 41% of global market revenue, supported by favorable reimbursement policies, increasing digital health adoption, and growing demand for remote patient care.
Mental health remains the largest and fastest-growing therapeutic area within digital therapeutics, while kidney disease management is emerging as one of the most attractive opportunities due to rising CKD prevalence and increasing healthcare costs.
Mental Health Digital Therapeutics: The Largest Competitive Battlefield
The mental health crisis has created one of the strongest growth opportunities in healthcare technology.
According to WHO estimates, anxiety and depression affect hundreds of millions of people worldwide, while treatment access remains limited across both developed and emerging markets.
Digital therapeutics companies are attempting to close this gap through clinically validated software programs that deliver cognitive behavioral therapy (CBT), behavioral coaching, medication support, and symptom monitoring.
The global mental health digital therapeutics market is estimated to reach USD 42.8 billion by 2034, growing at a CAGR exceeding 25%.
Major Direct Competitors in Mental Health DTx
Several companies are competing directly for patients, providers, employers, and healthcare payers.
| Company | Primary Focus | Competitive Strength |
|---|---|---|
| Click Therapeutics | Prescription digital therapeutics | Clinical evidence and pharma partnerships |
| Big Health | Insomnia and anxiety treatment | Digital CBT programs |
| Woebot Health | AI-powered mental health support | Conversational AI platform |
| Headspace Health | Meditation and behavioral health | Large consumer user base |
| Spring Health | Employer mental healthcare | Enterprise-focused model |
| Akili Interactive | ADHD treatment | FDA-authorized therapeutic gaming |
These companies compete on clinical outcomes, patient engagement rates, payer reimbursement, and healthcare partnerships.
As healthcare systems increasingly demand evidence-based solutions, companies with published clinical data are gaining a significant competitive advantage.
Kidney Disease Digital Therapeutics: A Fast-Growing Opportunity
While mental health receives most of the attention, kidney disease is quietly becoming one of the most important growth segments within digital therapeutics.
According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 35.5 million Americans are living with chronic kidney disease.
Alarmingly, nearly 90% of adults with CKD do not know they have the disease, highlighting a major opportunity for digital monitoring and early intervention solutions.
Digital therapeutics platforms are helping patients manage medication adherence, blood pressure, nutrition, fluid intake, and disease progression through continuous monitoring and personalized coaching.
Companies Competing in Kidney Disease Management
Unlike mental health, kidney disease remains a relatively fragmented market.
Companies such as Strive Health, Cricket Health, Monogram Health, CareDx, and several remote patient monitoring providers are expanding their digital care capabilities for CKD patients.
Competition increasingly focuses on reducing hospitalizations, delaying dialysis initiation, improving patient adherence, and lowering overall healthcare costs.
The Indirect Competitors Are Even Bigger
The greatest competitive threat to digital therapeutics companies often comes from outside the industry itself.
For mental health providers, indirect competitors include:
- Traditional psychologists and therapists
- Psychiatric hospitals
- Telepsychiatry providers
- Pharmaceutical treatments
- Employer wellness programs
For kidney disease management companies, indirect competitors include:
- Nephrology clinics
- Dialysis providers
- Hospital systems
- Remote monitoring vendors
- Pharmaceutical companies developing CKD therapies
These organizations may not classify themselves as digital therapeutics providers, but they compete for the same patients, reimbursement budgets, and healthcare contracts.
Fact-Rich Government and Healthcare Statistics
The market opportunity becomes even clearer when examining public health data.
| Government / Health Organization Data | Statistic |
| WHO Mental Health Data | Nearly 1 billion people live with mental disorders globally |
| WHO Depression Statistics | Depression affects approximately 280 million people worldwide |
| CDC Chronic Kidney Disease Data | 35.5 million U.S. adults have CKD |
| CDC CKD Awareness Data | About 90% of adults with CKD are unaware they have the disease |
| NIH Kidney Disease Data | CKD is among the leading causes of death globally |
| WHO Noncommunicable Disease Data | Chronic diseases account for 74% of global deaths annually |
These figures explain why investors, healthcare systems, and technology companies continue pouring capital into digital therapeutics development.
The Future of Competition
The next phase of competition will not be determined by who has the best mobile app.
Instead, winners will be the companies that demonstrate measurable clinical outcomes, secure reimbursement approval, integrate seamlessly into healthcare workflows, and prove they can reduce healthcare costs at scale.
As mental health disorders continue to rise and chronic kidney disease becomes an increasing burden on healthcare systems, digital therapeutics companies are positioning themselves to become an essential component of future healthcare delivery.
The race is no longer about creating digital health tools; it is about becoming a clinically trusted treatment option for millions of patients worldwide.
Get Easy Access
Access our exclusive, data-rich dashboard dedicated to the Therapeutics area sector – built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is part of Towards Healthcare Research and Consulting which is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium